TGF‐β limits IL‐33 production and promotes the resolution of colitis through regulation of macrophage function

Mϕs promote tissue injury or repair depending on their activation status and the local cytokine milieu. It remains unclear whether the immunosuppressive effects of transforming growth factor β (TGF‐β) serve a nonredundant role in Mϕ function in vivo. We generated Mϕ‐specific transgenic mice that exp...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of immunology Vol. 41; no. 7; pp. 2000 - 2009
Main Authors Rani, Reena, Smulian, Alan G., Greaves, David R., Hogan, Simon P., Herbert, De'Broski R.
Format Journal Article
LanguageEnglish
Published Weinheim WILEY‐VCH Verlag 01.07.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Mϕs promote tissue injury or repair depending on their activation status and the local cytokine milieu. It remains unclear whether the immunosuppressive effects of transforming growth factor β (TGF‐β) serve a nonredundant role in Mϕ function in vivo. We generated Mϕ‐specific transgenic mice that express a truncated TGF‐β receptor II under control of the CD68 promoter (CD68TGF‐βDNRII) and subjected these mice to the dextran sodium sulfate (DSS) model of colitis. CD68TGF‐βDNRII mice have an impaired ability to resolve colitic inflammation as demonstrated by increased lethality, granulocytic inflammation, and delayed goblet cell regeneration compared with transgene negative littermates. CD68TGF‐βDNRII mice produce significantly less IL‐10, but have increased levels of IgE and numbers of IL‐33+ Mϕs than controls. These data are consistent with associations between ulcerative colitis and increased IL‐33 production in humans and suggest that TGF‐β may promote the suppression of intestinal inflammation, at least in part, through direct effects on Mϕ function.
ISSN:0014-2980
1521-4141
DOI:10.1002/eji.201041135